Global Health growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+19.4%+12.7%+21.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+4.8%+9.8%+30.5%
+1.9%+9.1%+35.5%
+15.1%+0.7%+46.6%
+15.6%+0.7%+41.5%
+23.9%+10.7%+4.6%
+17.6%+16.6%+19.7%
+14.5%+1.9%−5.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MEDANTA₹1,283.00

Global Health Ltd.

· Pharma & Health
₹ CrorePeersMAXHEALTHAPOLLOHOSPFORTISGLAXOANTHEMAJANTPHARMIPCALABABBOTINDIAMcap ₹34,473 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+21.6+12.7+19.4—
EBITDA Growth—+30.5+9.8+4.8—
EBIT Growth—+35.5+9.1+1.9—
Net Income Growth—+46.6+0.7+15.1—
EPS Growth—+41.5+0.7+15.6—
Total Assets Growth—+4.6+10.7+23.9—
Total Equity Growth—+19.7+16.6+17.6—
Cash from Operations Growth—-5.0+1.9+14.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.